Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Jan 20, 2021

Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in...

Jan 13, 2021

FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA)...

Jan 11, 2021

Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons